Cronos Group Inc. - Common Share (CRON)
Healthcare › Medicinal Chemicals & Botanical Products
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 178% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- ROE of 0.6% — below-average profitability
- Revenue growing at 25% annually
Cronos Group Inc. - Common Share (CRON) is a Healthcare company operating in Medicinal Chemicals & Botanical Products, listed on the NASDAQ , with a market capitalisation of $1.1 billion . Key value metrics: P/E ratio 174.6, P/B ratio 1.00, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Cronos Group Inc. - Common Share — Fundamental Analysis Summary
Cronos Group Inc. - Common Share (CRON) is currently trading 178% above its Graham Number of $1.03, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 174.6x.
On financial health, CRON shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and modest return on equity of 0.6% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.05.
StockPik's composite Value Score for CRON is 72/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CRON reports a solid gross margin of 44.6% (sector average: 39.4%) and a negative operating margin of -8.0%.
CRON shows revenue growing at 25% year-over-year, with earnings declining at 123%.